Esperion Therapeutics (ESPR) EPS (Weighted Average and Diluted) (2019 - 2025)
Historic EPS (Weighted Average and Diluted) for Esperion Therapeutics (ESPR) over the last 7 years, with Q3 2025 value amounting to -$0.16.
- Esperion Therapeutics' EPS (Weighted Average and Diluted) fell 666.67% to -$0.16 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.54, marking a year-over-year increase of 1562.5%. This contributed to the annual value of -$0.03 for FY2024, which is 9872.39% up from last year.
- According to the latest figures from Q3 2025, Esperion Therapeutics' EPS (Weighted Average and Diluted) is -$0.16, which was down 666.67% from -$0.06 recorded in Q2 2025.
- In the past 5 years, Esperion Therapeutics' EPS (Weighted Average and Diluted) registered a high of $0.34 during Q1 2024, and its lowest value of -$3.5 during Q1 2021.
- Over the past 5 years, Esperion Therapeutics' median EPS (Weighted Average and Diluted) value was -$0.5 (recorded in 2023), while the average stood at -$0.87.
- In the last 5 years, Esperion Therapeutics' EPS (Weighted Average and Diluted) soared by 14303.8% in 2024 and then tumbled by 16176.47% in 2025.
- Quarter analysis of 5 years shows Esperion Therapeutics' EPS (Weighted Average and Diluted) stood at -$2.39 in 2021, then soared by 69.03% to -$0.74 in 2022, then soared by 32.43% to -$0.5 in 2023, then soared by 77.73% to -$0.11 in 2024, then tumbled by 43.7% to -$0.16 in 2025.
- Its EPS (Weighted Average and Diluted) was -$0.16 in Q3 2025, compared to -$0.06 in Q2 2025 and -$0.21 in Q1 2025.